HomeAI · summaries
Storia in 8 fonti
Novartis del-desiran drug trial fails, stock drops 9%
The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis RNA drug falls short in rare muscle disease study
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
- ·
cnbc.com
Pharma major Novartis falls 10% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
